2012 Annual Meeting in Tampa, FL, April 29-May 2
Pre-Meeting Workshop: MTM Boot Camp The Business of Patient Care: Incorporating Comprehensive Medication Management (MTM) into your Practice
Where do you “fit” in the new health care system as a neuropsychiatric pharmacist? This day-long workshop will begin with an update on the health care system. The emphasis will be on the role of the pharmacist in the new organizational structures of the medical home and accountable care organizations.
The program will then demonstrate what payers want from pharmacists who wish to provide medication management services. Keys to defining your service, recruiting patients, demonstrating your value, charging for your services and expanding your service will all be demonstrated.
This workshop will provide critical information to pharmacists in all practice settings. You will get important questions answered and understand what changes are needed to achieve and maintain a successful practice. You will also have the opportunity to learn from individuals in the private sector who have experience in delivering medication management services. Join us with the goal of making your service even more successful in 2012.
Recertification Programming Learning Objectives
Evaluating Clinical Trials in Anxiety Disorders
Speaker: Laura Mandos, PharmD, Associate Professor of Clinical Pharmacy, Philadelphia College of Pharmacy, Philadelphia, PAEvidence Based Practice Live/Self-Study Learning Objectives
- Discuss unique issues related to the design of clinical trials of anxiety disorders.
- Discuss the rating scales used in clinical trials for specific anxiety disorders.
- Recommend clinical trial duration lengths for specific anxiety disorders.
- Identify the advantages and disadvantages of using fixed versus flexible dosing in clinical trials of anxiety disorders.
- Compare and contrast measures of response versus remission for clinical trials of anxiety disorders.
Note: the anxiety disorders that will be reviewed are: generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, and obsessive-compulsive disorder.
Home-Study Literature Analysis Learning Objectives
To Be Determined
Pharmacological Basis of Treatment of Schizophrenia
Speaker: Sheila Botts, PharmD, BCPP, Assistant Professor, University of Kentucky, Lexington, KYEvidence Based Practice Live/Self-Study Learning Objectives
- Review pharmacological targets of current drug therapy for schizophrenia.
- Compare and contrast mechanisms of action of antipsychotics and the relevance to effectiveness and tolerability.
- Discuss pathophysiological models for drug development.
Home-Study Literature Analysis Learning Objectives
To Be Determined
Treatment Resistant Depression
Speaker: Lynn Crismon, PharmD, BCPP, Professor, University of Texas, Austin, TXEvidence Based Practice Live/Self-Study Learning Objectives
- Identify the relative merit of various treatment options when first-line interventions do not result in adequate clinical improvement of depression
- Outline the role of serial monotherapies in individuals who do not adequately improve with first line therapies
- Delineate appropriate combination interventions for treatment resistant depression
- Discuss the role of vagal nerve stimulation in treatment-resistant depression
Home-Study Literature Analysis Learning Objectives
To Be Determined
Autistic Disorder and other Pervasive Developmental Disorders
Speaker: William H. Benefield, Jr., PharmD, BCPP, FASCP; Clinical Assistant Professor of Pharmacology, Division of Pharmacotherapy, The University of Texas Health Science Center at San Antonio; Clinical Assistant Professor of Pharmacology, The University of Texas at Austin; Consultant Psychopharmacologist, The Center for Health Care Services; Consultant -- PharMerica, San Antonio, TexasEvidence Based Practice Live/Self-Study Learning Objectives
- Differentiate between the diagnostic criteria for Autistic Disorder and the other subtypes of Pervasive Developmental Disorders
- Discuss the proposed pathophysiology and etiology within the Pervasive Developmental Disorders spectrum
- Identify target symptoms associated with Pervasive Developmental Disorders which are responsive to pharmacotherapy
- Discuss the role of antipsychotics, antidepressants, mood stabilizers, alpha-adrenergic agonists, opiate antagonists, and beta blockers in treating symptoms of Pervasive Developmental Disorder.
Home-Study Literature Analysis Learning Objectives
To Be Determined
Personality Disorders: Clinical Diagnosis and Evidence-Based Treatment
Speaker: Sally Guthrie, PharmD, BCPP, Associate Professor, University of Michigan, Ann Arbor, MIEvidence Based Practice Live/Self-Study Learning Objectives
- Identify clinical features of the various personality disorders and clusters per DSM-IV criteria.
- Outline target symptoms presenting in personality disorders that are most likely to respond to pharmacotherapy and the most effective ways to monitor response to treatment.
- Define a pharmacotherapy plan for the treatment of personality disorders using patient specific factors and an evidence-based medicine approach.
Home-Study Literature Analysis Learning Objectives
To Be Determined